Onconetix Readies 19 Robot Deliveries and H2 2026 Acquisition of Realbotix
Onconetix’s pending acquisition target Realbotix expects to deliver 19 AI-powered humanoid robots during March, April and May 2026 as it scales production capacity. The companies entered a definitive share exchange agreement for Onconetix to acquire Realbotix LLC in an all-stock deal, with closing anticipated in H2 2026 pending approvals.
1. Realbotix Delivery Schedule
Realbotix has announced an expected delivery of 19 AI-powered humanoid robots and corresponding AI implementations across March, April and May 2026. This rollout reflects accelerated production efforts aimed at meeting growing enterprise and consumer demand.
2. Share Exchange Agreement
On February 12, 2026, Onconetix entered into a definitive share exchange agreement to acquire 100% of Realbotix LLC’s outstanding equity interests. The all-stock transaction will issue Onconetix shares in exchange for Realbotix ownership.
3. Closing Timeline and Conditions
The acquisition is slated to close in the second half of 2026, subject to Onconetix shareholder approval, receipt of required regulatory consents and satisfaction of customary closing conditions. A Registration Statement on Form S-4 and proxy materials will be filed ahead of the vote.
4. Strategic Outlook
The deal extends Onconetix’s commercial-stage biotech portfolio into AI-powered robotics, potentially generating new revenue streams. The combined entity is expected to list on Nasdaq post-closing, broadening its market exposure and investor base.